Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT07725406
What this trial is testing

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM)
Weill Medical College of Cornell University 32
Testing effectiveness (Phase 2)Study completedNCT02987400
What this trial is testing

Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Arbeitsgemeinschaft medikamentoese Tumortherapie 22
Early research (Phase 1)Study completedNCT04231747
What this trial is testing

CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma Non-HodgkinAgressive LymphomaDiffuse-large B-cell Lymphoma (DLBCL)
Juno Therapeutics, a Subsidiary of Celgene 24
Early research (Phase 1)Study completedNCT03467373
What this trial is testing

Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Who this might be right for
B-Cell LymphomaNon-Hodgkin Lymphoma
Hoffmann-La Roche 111
Testing effectiveness (Phase 2)Study completedNCT01562977
What this trial is testing

Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

Who this might be right for
Aggressive LymphomaDiffuse Large B-cell LymphomaMantle Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 82
Testing effectiveness (Phase 2)Ended earlyNCT02592876
What this trial is testing

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma, B-cellLymphoma, Large B-Cell, DiffuseLymphoma, Follicular, Grade 3b+1 more
Seagen Inc. 81
Early research (Phase 1)Study completedNCT00655837
What this trial is testing

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Who this might be right for
Lymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Seagen Inc. 33
Early research (Phase 1)Active Not RecruitingNCT05753501
What this trial is testing

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Who this might be right for
Hematologic Cancer
AbbVie 135
Large-scale testing (Phase 3)Ended earlyNCT04236141
What this trial is testing

Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Who this might be right for
Diffuse, Large B-Cell, Lymphoma
Hoffmann-La Roche 42
Very early researchStudy completedNCT02405078
What this trial is testing

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center 35
Early research (Phase 1)Study completedNCT03798314
What this trial is testing

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Who this might be right for
Recurrent Nervous System LymphomaRecurrent Primary Vitreoretinal DLBCLRefractory Nervous System Lymphoma+1 more
Mayo Clinic 3
Early research (Phase 1)Study completedNCT03688152
What this trial is testing

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Incyte Corporation 9
Early research (Phase 1)UnknownNCT05039658
What this trial is testing

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Who this might be right for
DLBCL
Innovent Biologics (Suzhou) Co. Ltd. 50
Not applicableStudy completedNCT07103486
What this trial is testing

Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Novartis Pharmaceuticals 264
Testing effectiveness (Phase 2)Looking for participantsNCT07062627
What this trial is testing

Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

Who this might be right for
Primary CNS Lymphoma (PCNSL)Diffuse Large B Cell Lymphoma (DLBCL)
Hyungwoo Cho 12
Testing effectiveness (Phase 2)UnknownNCT05115409
What this trial is testing

Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

Who this might be right for
Relapsed or Refractory DLBCL
Sun Yat-sen University 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT05583149
What this trial is testing

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Who this might be right for
Refractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHL+10 more
Patrick C. Johnson, MD 28
Testing effectiveness (Phase 2)Ended earlyNCT03287817
What this trial is testing

Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

Who this might be right for
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Autolus Limited 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07735533
What this trial is testing

UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

Who this might be right for
Lymphoma, B CellLymphoma Non-HodgkinHigh Grade B Cell Lymphoma+4 more
Umoja Biopharma 274
Early research (Phase 1)Study completedNCT03527147
What this trial is testing

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

Who this might be right for
NHLDLBCLNon-hodgkin's Lymphoma+1 more
Acerta Pharma BV 30
Next Page